Clinical Trial Update: Phase II Study of Efficacy and Safety of HSK39297 Tablet in Treatment of Patients with Primary IgAN [Phase 2]

View source ↗

Summary

This clinical trial update indicates that a Phase II study of HSK39297 tablet for primary IgA nephropathy is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Iga Nephropathy

Drugs mentioned

• HSK39297 Tablet (HSK39297)

Snippet

Sponsor: Haisco Pharmaceutical Group Co., Ltd. | Conditions: IgA Nephropathy (IgAN) | Phase 2 | Status: RECRUITING